A Study of E2022 Tape Formulation (Overlay-integrated E2022 18 mg Tape Formulation) for Different Application Sites and Intervals in Japanese Healthy Elderly Males

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Mar 2015

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Donepezil (Primary)
Indications Alzheimer's disease; Dementia; Down syndrome; Lewy body disease; Vascular dementia
Focus Adverse reactions
Sponsors Eisai Co Ltd

12 Mar 2015 Status changed from recruiting to completed.
21 Oct 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
27 Aug 2014 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com